•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

S06758 Summary:

BILL NOS06758A
 
SAME ASNo Same As
 
SPONSORFERNANDEZ
 
COSPNSR
 
MLTSPNSR
 
Amd §§3331 & 3309, Pub Health L
 
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Go to top

S06758 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         6758--A
 
                               2025-2026 Regular Sessions
 
                    IN SENATE
 
                                     March 24, 2025
                                       ___________
 
        Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
          printed  to  be committed to the Committee on Health -- recommitted to
          the Committee on Health in accordance with Senate Rule 6,  sec.  8  --
          committee  discharged,  bill amended, ordered reprinted as amended and
          recommitted to said committee

        AN ACT to amend the public health law, in relation to requiring  practi-
          tioners  to  discuss  certain  risks  with  a  patient  who  is  being
          prescribed a controlled substance or an opioid analgesic
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1. Subdivision 9 of section 3331 of the public health law, as
     2  added by chapter 732 of the laws of 2022, is amended to read as follows:
     3    9. (a) When a patient seeks treatment for  any  [neuromusculoskeletal]
     4  condition  that  causes  pain, where a practitioner considers [an opioid
     5  treatment] prescription of a schedule II controlled  substance  for  the
     6  treatment  of pain or any other opioid drug which is a prescription drug
     7  for acute  or  chronic  pain  and  again  prior  to  issuing  the  third
     8  prescription  of the course of treatment, the practitioner shall consid-
     9  er, discuss with the patient as set  forth  in  paragraph  (b)  of  this
    10  subdivision,  and,  as appropriate, refer or prescribe non-opioid treat-
    11  ment alternatives, based on the  practitioner's  clinical  judgment  and
    12  following  generally  accepted national professional or treatment guide-
    13  lines, and consistent with patient preference and consent, before start-
    14  ing a patient on opioid treatment. For the purposes of this subdivision,
    15  non-opioid treatment alternatives  include,  but  are  not  limited  to:
    16  acupuncture,  chiropractic,  massage  therapy, physical therapy, occupa-
    17  tional therapy, cognitive behavioral  therapy,  non-opioid  medications,
    18  interventional  treatments and non-clinical activities such as exercise.
    19  The practitioner shall inform the patient that some treatments  may  not
    20  be covered by the patient's health coverage.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD11164-02-5

        S. 6758--A                          2
 
     1    (b)  A  practitioner  shall discuss with the patient, or the patient's
     2  parent or guardian if the patient is under eighteen years of age and  is
     3  not  an  emancipated  minor,  the  risks associated with the drugs being
     4  prescribed, including but not limited to:
     5    (i)  the  risks of addiction and overdose associated with opioid drugs
     6  and the dangers of taking opioid drugs with alcohol, benzodiazepines and
     7  other central nervous system depressants;
     8    (ii) the reasons why the prescription is necessary;
     9    (iii) alternative treatments that may be available; and
    10    (iv) the risks associated with the use of the drugs being  prescribed,
    11  specifically  that  opioids  are  highly  addictive,  even when taken as
    12  prescribed, that there is a risk of developing a physical or  psycholog-
    13  ical  dependence  on  the  controlled  substance,  and that the risks of
    14  taking more opioids than prescribed, or  mixing  sedatives,  benzodiaze-
    15  pines   or  alcohol  with  opioids,  can  result  in  fatal  respiratory
    16  depression.
    17    (c) The department shall develop and make available  to  practitioners
    18  guidelines for the discussion required by this subdivision.
    19    (d)  The requirements of this subdivision shall not apply for patients
    20  being treated under any of the following circumstances:    treatment  of
    21  cancer;  hospice or other end-of-life care; post-surgery treatment imme-
    22  diately following a surgical procedure; or in a medical emergency.   For
    23  purposes  of this subdivision, "medical emergency" means an acute injury
    24  or illness that poses an immediate risk to a person's life or health.
    25    § 2. Paragraph (a) of subdivision 3 of  section  3309  of  the  public
    26  health  law  is  amended  by  adding a new subparagraph (vii) to read as
    27  follows:
    28    (vii) "Opioid analgesics" means the medicines buprenorphine, butorpha-
    29  nol,  codeine,  hydrocodone,  hydromorphone,  levorphanol,   meperidine,
    30  methadone,  morphine,  nalbuphine,  oxycodone, oxymorphone, pentazocine,
    31  propoxyphene as well as their brand names, isomers and combinations.
    32    § 3. Subdivision 7 of section 3309 of the public health law, as  added
    33  by chapter 803 of the laws of 2021, is amended to read as follows:
    34    7. [With] For the first opioid analgesic prescription [to a particular
    35  patient]  of  [an opioid of each] a calendar year that is greater than a
    36  one week's supply, for use in a setting other than a general hospital or
    37  nursing home under article twenty-eight  of  this  chapter  or  facility
    38  under  article  thirty-one  of the mental hygiene law, or when a practi-
    39  tioner is prescribing a controlled substance to a patient under the care
    40  of hospice as defined by section four thousand two of this chapter,  the
    41  prescriber  shall  counsel  the  patient  on  the risks of overdose, and
    42  prescribe an opioid antagonist when any of the  following  risk  factors
    43  are  present:  (a) a history of substance use disorder; (b) high dose or
    44  cumulative prescriptions that result in ninety morphine milligram equiv-
    45  alents or higher per day; (c) concurrent use of opioids and  benzodiaze-
    46  pine or nonbenzodiazepine sedative hypnotics.
    47    § 4. This act shall take effect immediately.
Go to top